A phase II study of mitomycin C, cisplatin and protracted infusional 5-fluorouracil in advanced pancreatic carcinoma

efficacy and low toxicity

R. D. Petty (Lead / Corresponding author), M. C. Nicolson, S. Skaria, T. S. Sinclair, L. M. Samuel, M. Koruth, Aberdeen Pancreatic Cancer Focus Group

    Research output: Contribution to journalArticle

    14 Citations (Scopus)

    Abstract

    BACKGROUND: The effective treatment of unresectable pancreatic carcinoma represents a formidable challenge. There is a need to develop systemic therapies which combine efficacy with acceptable toxicity. The current 'gold standard' gemcitabine gives an objective response rate of the order of 20% and median survival up to 6 months. Here we have evaluated the efficacy and toxicity of mitomycin C, cisplatin and protracted infusional 5-fluorouracil (MCF).

    PATIENTS AND METHODS: Forty-five patients with locally advanced (13 patients) or metastatic (32 patients) pancreatic carcinoma were treated with mitomycin C 7 mg/m2 6 weekly, cisplatin 60 mg/m2 3 weekly and protracted venous infusion 5-FU 300 mg/m2/day. Patients were evaluated for response after three cycles and received six cycles in total in the absence of progressive disease or poor tolerance. Median age was 62 (45-75) years; 41 patients were World Health Organization performance status 0-1.

    RESULTS: Treatment was well tolerated with 36 (84%) patients completing three or more cycles. Grade 3 or 4 toxicities were uncommon: anaemia in three patients (7%), mucositis in two (5%), nausea and vomiting in three (7%) and diarrhoea in one (1%). An objective response was seen in 21 (46%) patients. There was one complete response. The median survival overall was 7.1 months and 10.5 months in responders. The median duration of response was 4.3 months. One-year survival was 29%, 2-year survival was 18%.

    CONCLUSIONS: MCF combines efficacy with low toxicity in the treatment of advanced pancreatic carcinoma. The efficacy is at least comparable and may be superior to single-agent gemcitabine and MCF may therefore provide a cost-effective alternative.

    Original languageEnglish
    Pages (from-to)1100-1105
    Number of pages6
    JournalAnnals of Oncology
    Volume14
    Issue number7
    DOIs
    Publication statusPublished - Jul 2003

    Fingerprint

    Mitomycin
    Fluorouracil
    Cisplatin
    gemcitabine
    Survival
    Mucositis
    Pancreatic Carcinoma
    Therapeutics
    Nausea
    Vomiting
    Anemia
    Diarrhea
    Costs and Cost Analysis

    Keywords

    • Aged
    • Antineoplastic Combined Chemotherapy Protocols
    • Carcinoma
    • Cisplatin
    • Female
    • Fluorouracil
    • Humans
    • Infusions, Intravenous
    • Male
    • Middle Aged
    • Mitomycins
    • Pancreatic Neoplasms
    • Survival Analysis
    • Treatment Outcome

    Cite this

    Petty, R. D., Nicolson, M. C., Skaria, S., Sinclair, T. S., Samuel, L. M., Koruth, M., & Aberdeen Pancreatic Cancer Focus Group (2003). A phase II study of mitomycin C, cisplatin and protracted infusional 5-fluorouracil in advanced pancreatic carcinoma: efficacy and low toxicity. Annals of Oncology, 14(7), 1100-1105. https://doi.org/10.1093/annonc/mdg278
    Petty, R. D. ; Nicolson, M. C. ; Skaria, S. ; Sinclair, T. S. ; Samuel, L. M. ; Koruth, M. ; Aberdeen Pancreatic Cancer Focus Group. / A phase II study of mitomycin C, cisplatin and protracted infusional 5-fluorouracil in advanced pancreatic carcinoma : efficacy and low toxicity. In: Annals of Oncology. 2003 ; Vol. 14, No. 7. pp. 1100-1105.
    @article{12b361e47ded4338911048d2fcc2f8e8,
    title = "A phase II study of mitomycin C, cisplatin and protracted infusional 5-fluorouracil in advanced pancreatic carcinoma: efficacy and low toxicity",
    abstract = "BACKGROUND: The effective treatment of unresectable pancreatic carcinoma represents a formidable challenge. There is a need to develop systemic therapies which combine efficacy with acceptable toxicity. The current 'gold standard' gemcitabine gives an objective response rate of the order of 20{\%} and median survival up to 6 months. Here we have evaluated the efficacy and toxicity of mitomycin C, cisplatin and protracted infusional 5-fluorouracil (MCF).PATIENTS AND METHODS: Forty-five patients with locally advanced (13 patients) or metastatic (32 patients) pancreatic carcinoma were treated with mitomycin C 7 mg/m2 6 weekly, cisplatin 60 mg/m2 3 weekly and protracted venous infusion 5-FU 300 mg/m2/day. Patients were evaluated for response after three cycles and received six cycles in total in the absence of progressive disease or poor tolerance. Median age was 62 (45-75) years; 41 patients were World Health Organization performance status 0-1.RESULTS: Treatment was well tolerated with 36 (84{\%}) patients completing three or more cycles. Grade 3 or 4 toxicities were uncommon: anaemia in three patients (7{\%}), mucositis in two (5{\%}), nausea and vomiting in three (7{\%}) and diarrhoea in one (1{\%}). An objective response was seen in 21 (46{\%}) patients. There was one complete response. The median survival overall was 7.1 months and 10.5 months in responders. The median duration of response was 4.3 months. One-year survival was 29{\%}, 2-year survival was 18{\%}.CONCLUSIONS: MCF combines efficacy with low toxicity in the treatment of advanced pancreatic carcinoma. The efficacy is at least comparable and may be superior to single-agent gemcitabine and MCF may therefore provide a cost-effective alternative.",
    keywords = "Aged, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Cisplatin, Female, Fluorouracil, Humans, Infusions, Intravenous, Male, Middle Aged, Mitomycins, Pancreatic Neoplasms, Survival Analysis, Treatment Outcome",
    author = "Petty, {R. D.} and Nicolson, {M. C.} and S. Skaria and Sinclair, {T. S.} and Samuel, {L. M.} and M. Koruth and {Aberdeen Pancreatic Cancer Focus Group}",
    year = "2003",
    month = "7",
    doi = "10.1093/annonc/mdg278",
    language = "English",
    volume = "14",
    pages = "1100--1105",
    journal = "Annals of Oncology",
    issn = "0923-7534",
    publisher = "Oxford University Press",
    number = "7",

    }

    Petty, RD, Nicolson, MC, Skaria, S, Sinclair, TS, Samuel, LM, Koruth, M & Aberdeen Pancreatic Cancer Focus Group 2003, 'A phase II study of mitomycin C, cisplatin and protracted infusional 5-fluorouracil in advanced pancreatic carcinoma: efficacy and low toxicity', Annals of Oncology, vol. 14, no. 7, pp. 1100-1105. https://doi.org/10.1093/annonc/mdg278

    A phase II study of mitomycin C, cisplatin and protracted infusional 5-fluorouracil in advanced pancreatic carcinoma : efficacy and low toxicity. / Petty, R. D. (Lead / Corresponding author); Nicolson, M. C.; Skaria, S.; Sinclair, T. S.; Samuel, L. M.; Koruth, M.; Aberdeen Pancreatic Cancer Focus Group.

    In: Annals of Oncology, Vol. 14, No. 7, 07.2003, p. 1100-1105.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - A phase II study of mitomycin C, cisplatin and protracted infusional 5-fluorouracil in advanced pancreatic carcinoma

    T2 - efficacy and low toxicity

    AU - Petty, R. D.

    AU - Nicolson, M. C.

    AU - Skaria, S.

    AU - Sinclair, T. S.

    AU - Samuel, L. M.

    AU - Koruth, M.

    AU - Aberdeen Pancreatic Cancer Focus Group

    PY - 2003/7

    Y1 - 2003/7

    N2 - BACKGROUND: The effective treatment of unresectable pancreatic carcinoma represents a formidable challenge. There is a need to develop systemic therapies which combine efficacy with acceptable toxicity. The current 'gold standard' gemcitabine gives an objective response rate of the order of 20% and median survival up to 6 months. Here we have evaluated the efficacy and toxicity of mitomycin C, cisplatin and protracted infusional 5-fluorouracil (MCF).PATIENTS AND METHODS: Forty-five patients with locally advanced (13 patients) or metastatic (32 patients) pancreatic carcinoma were treated with mitomycin C 7 mg/m2 6 weekly, cisplatin 60 mg/m2 3 weekly and protracted venous infusion 5-FU 300 mg/m2/day. Patients were evaluated for response after three cycles and received six cycles in total in the absence of progressive disease or poor tolerance. Median age was 62 (45-75) years; 41 patients were World Health Organization performance status 0-1.RESULTS: Treatment was well tolerated with 36 (84%) patients completing three or more cycles. Grade 3 or 4 toxicities were uncommon: anaemia in three patients (7%), mucositis in two (5%), nausea and vomiting in three (7%) and diarrhoea in one (1%). An objective response was seen in 21 (46%) patients. There was one complete response. The median survival overall was 7.1 months and 10.5 months in responders. The median duration of response was 4.3 months. One-year survival was 29%, 2-year survival was 18%.CONCLUSIONS: MCF combines efficacy with low toxicity in the treatment of advanced pancreatic carcinoma. The efficacy is at least comparable and may be superior to single-agent gemcitabine and MCF may therefore provide a cost-effective alternative.

    AB - BACKGROUND: The effective treatment of unresectable pancreatic carcinoma represents a formidable challenge. There is a need to develop systemic therapies which combine efficacy with acceptable toxicity. The current 'gold standard' gemcitabine gives an objective response rate of the order of 20% and median survival up to 6 months. Here we have evaluated the efficacy and toxicity of mitomycin C, cisplatin and protracted infusional 5-fluorouracil (MCF).PATIENTS AND METHODS: Forty-five patients with locally advanced (13 patients) or metastatic (32 patients) pancreatic carcinoma were treated with mitomycin C 7 mg/m2 6 weekly, cisplatin 60 mg/m2 3 weekly and protracted venous infusion 5-FU 300 mg/m2/day. Patients were evaluated for response after three cycles and received six cycles in total in the absence of progressive disease or poor tolerance. Median age was 62 (45-75) years; 41 patients were World Health Organization performance status 0-1.RESULTS: Treatment was well tolerated with 36 (84%) patients completing three or more cycles. Grade 3 or 4 toxicities were uncommon: anaemia in three patients (7%), mucositis in two (5%), nausea and vomiting in three (7%) and diarrhoea in one (1%). An objective response was seen in 21 (46%) patients. There was one complete response. The median survival overall was 7.1 months and 10.5 months in responders. The median duration of response was 4.3 months. One-year survival was 29%, 2-year survival was 18%.CONCLUSIONS: MCF combines efficacy with low toxicity in the treatment of advanced pancreatic carcinoma. The efficacy is at least comparable and may be superior to single-agent gemcitabine and MCF may therefore provide a cost-effective alternative.

    KW - Aged

    KW - Antineoplastic Combined Chemotherapy Protocols

    KW - Carcinoma

    KW - Cisplatin

    KW - Female

    KW - Fluorouracil

    KW - Humans

    KW - Infusions, Intravenous

    KW - Male

    KW - Middle Aged

    KW - Mitomycins

    KW - Pancreatic Neoplasms

    KW - Survival Analysis

    KW - Treatment Outcome

    U2 - 10.1093/annonc/mdg278

    DO - 10.1093/annonc/mdg278

    M3 - Article

    VL - 14

    SP - 1100

    EP - 1105

    JO - Annals of Oncology

    JF - Annals of Oncology

    SN - 0923-7534

    IS - 7

    ER -